<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825653/" ref="ordinalpos=1301&amp;ncbi_uid=2273064&amp;link_uid=PMC2825653" image-link="/pmc/articles/PMC2825653/figure/fig5/" class="imagepopup">Figure 5.  From: Epidermal Growth Factor (EGF) Treatment on Multipotential Stromal Cells (MSCs). Possible Enhancement of Therapeutic Potential of MSC. </a></div><br /><div class="p4l_captionBody">Simplified diagram of EGFR/ErbB1 signaling pathways in MSC physiology. EGFR/ErbB1 ligands activate PLCγ pathway, p42/44 MAPK pathway, and PI3K/Akt pathways in MSCs [3]. PLCγ pathway plays a pivotal role in motogenic activity, whereas p42/44 MAPK pathway plays a key role in mitogenic activity and paracrine activities of certain factors such as VEGF    [42, 43, 66, 67].  Sustained and strong activation of p42/44 MAPK pathway exerts cytoprotective and pro-osteogenic effects    [44, 47], whereas PI3K/Akt pathway might exert anti-osteogenic effects [46].</div></div>